Drug Repurposing 57 well-known drugs for three COVID-19 targets: Mpro, Spike, RdRp

06 July 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The pandemic that we are currently living through, caused by SARS COVID-19, changed the way we perceive deadly diseases along with our comprehension of efficacious drugs. In this project, we compare 57 repurposable drugs from different categories like anti-inflammatory, anticancer, anticoagulant, antiviral, anti-parasitic, antidepressant, Parkinson’s disease drugs, and discontinued drugs, to identify the best drugs with strongest binding affinities, that can be considered for treating COVID-19. We identified three target proteins- Main protease (PDB ID: 6LU7), Spike Glycoprotein with human receptor ACE2 (PDB ID: 6M0J), and RNA-dependent RNA polymerase (RdRp) in complex with Remdesivir (PDB ID: 7BV2) which are responsible for transcription, entrance into host’s cell and viral replication respectively. We used AutoDock Vina for docking, and based our results on the binding affinity and hydrogen bond interactions. We shortlisted 15 drugs- Vilazodone, Lopinavir, Ritonavir, Darunavir, Selinexor, Etoposide, Nintedanib, Methylprednisolone, Hydrocortisone, Tolcapone, Apixaban, Rivaroxaban, Dabigatran, Betrixaban, and Amprenavir- that showcased comparable or higher affinity than Remdesivir with all of our three target proteins, and recommend these for further studies.

Keywords

drug repurposing
COVID-19
anticancer
anticoagulant
anti-inflammatory
anti-parasitic
Nitriles
antiviral

Supplementary materials

Title
Description
Actions
Title
Supplementary File-A
Description
Remdesivir superimposed with best ligands when docked with RdRp (7BV2) protein with corresponding binding affinities.
Actions
Title
Supplementary File-B
Description
Remdesivir superimposed with best ligands when docked with Spike (6M0J) protein with corresponding binding affinities.
Actions
Title
Supplementary File-C
Description
Remdesivir superimposed with best ligands when docked with Mpro (6LU7) protein with corresponding binding affinities.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.